comprehensive -WSS

comprehensive

author：entertainment 2025-08-23 18:38:00 - browse：754

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

LONDON — A U.K. government agency on Tuesday said that it won’t recommend Eli Lilly’s Mounjaro — part of a new class of medications that help patients lose weight — for people with type 2 diabetes without additional evidence.

Mounjaro, also known as tirzepatide, has U.S. approval for type 2 diabetes and is expected to win the regulatory green light for obesity later this year. It is one of several medications, along with Wegovy and Ozempic from Novo Nordisk, that have shown dramatic weight loss results, creating a surge in demand and blockbuster sales expectations.

But in draft guidance, the U.K.’s National Institute for Health and Care Excellence, which assesses the cost-effectiveness of medications, said it had asked Lilly for more data “to address the uncertainties in the clinical evidence, when compared to all relevant alternative treatments.” NICE recommendations are used by the National Health Service to determine whether to provide certain medications.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： SNAP should offer more nutrition education

focus

WSS

Christmas in the PICU brings some surprising joy

HCA sued by state AG for quality issues at Mission Health

Violet CEO on training clinicians to promote more inclusive care

Why health care costs have stayed mostly flat since 2010

SNAP should offer more nutrition education

Drastic changes should bring profitability, startup health insurers say

hotspot

comprehensive

focus

Drug repurposing or repositioning? The language matters

American woman, child freed after being kidnapped in Haiti last month

Peter Hotez and the public health issue of online harassment

Grail spinoff by Illumina should end disastrous merger attempt

Apple is now the first public company to be valued at $3 trillion

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

Virginia high school admissions case could be legal follow

Virtual care provider acquires bankrupt Pear's prescription apps

Dobbs anniversary: the lost opportunity of abortion as health care

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

knowledge

Methadone doses haven’t kept up in the age of fentanyl

Keeping primary care docs in field isn't impossible, says AAFP CEO

Drastic changes should bring profitability, startup health insurers say

Shkreli is convicted of fraud. Can pharma finally slam the door on him?

Virtual care provider acquires bankrupt Pear's prescription apps

Violet CEO on training clinicians to promote more inclusive care

leisure time

focus

Wikipedia

leisure time